Wolfgang Miesbach: Why Patient-Reported Outcomes (PROs) Are Essential for Hemophilia Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about his recent article published in PubMed, adding:
“Thrilled that this new open-access review, ‘Patient-Reported Outcomes in Haemophilia Gene Therapy,’ is out.
Three AAV gene therapies approved in the West since 2022, yet uptake has been slow — Beqvez discontinued, Roctavian withdrawn.
PRO evidence can help bridge the gap between trial efficacy and real-world adoption by showing what gene therapy means for everyday life.
Bleeding rates capture efficacy, but not what patients experience. Across six trials and 12 instruments, the signal is consistent:
Disease-specific QoL improved 6–15 points, beyond clinically important thresholds.
The new coreHEM-MHO measures what older tools can’t — durability anxiety, disease identity adjustment
Cost-effectiveness rests almost entirely on these QoL gains; life-year gains are negligible
The paradox: instruments built two decades ago can penalise patients who no longer bleed, because ‘not applicable’ isn’t an option.
We’re underestimating the very benefit we’re trying to prove.
Priorities: standardised coreHEM measurement, long-term registries (WFH GTR, EAHAD-GTD), and certified centres equipped for PRO follow-up.
With the FDA and EMA now recognising PROs in regulatory and HTA decisions, and the economic case resting on quality of life, we owe it to patients to measure it properly.”
Title: Overview of Patient-Reported Outcomes in Haemophilia Gene Therapy Open Access
Authors: Wolfgang Miesbach
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Sep 18, 2026, 17:48Ronak H. Mistry: Updated ASH Guidelines Bring New Focus to Iron Deficiency
-
Sep 18, 2026, 17:32Hassan Kawtharany: New Ferritin Cutoffs for the Diagnosis of Iron Deficiency With or Without Anemia
-
Sep 18, 2026, 17:20Abhishek G P: GAVE as an Important Cause of Chronic Gastrointestinal Blood Loss
-
Sep 18, 2026, 17:08Irem Karaman Sebin: ASH 2026 Changes a Key Concept in Iron Deficiency
-
Sep 18, 2026, 16:51Adarsh Krishnan Sundara Rajan: Is VTE the Most Underdiagnosed Critical Threat in Modern Healthcare?
-
Sep 18, 2026, 16:19CRISPR and Hemophilia: The Next Frontier of In Vivo Gene Editing
-
Sep 18, 2026, 16:13Christian Irsara: PF4 Immunothrombosis Following Natural Adenovirus Infection
-
Sep 18, 2026, 16:10Leo Nicolai։ The Spleen Emerges as a Key Regulator of Thromboinflammation
-
Sep 18, 2026, 16:05Targeting Factor XI to Reduce Thrombosis Without Compromising Hemostasis – ISTH